Abstract
KIAA1363 is a serine hydrolase whose activity has been shown to be positively associated with tumor cell invasiveness. Thus, inhibitors of KIAA1363 represent a novel targeted therapy approach towards cancer. AX11890 ((1-bromo-2-naphthyl) N,N-dimethylcarbamate) was identified as a KIAA1363 inhibitor with an IC(50) value of 1.2 μM and was shown using ESI-MS to carbamylate the catalytic residue Ser(191). SAR studies explored both substitution of the 1-bromo group and derivatization of the 6-position. Activity-based protein profiling demonstrated AX13057 inhibited tumor-localized KIAA1363 in SK-OV-3 xenograft-bearing mice.
Copyright © 2012. Published by Elsevier Ltd.
MeSH terms
-
Animals
-
Carbamates / chemical synthesis
-
Carbamates / chemistry*
-
Carbamates / pharmacology*
-
Carbamates / therapeutic use
-
Carboxylic Ester Hydrolases / antagonists & inhibitors*
-
Carboxylic Ester Hydrolases / metabolism
-
Cell Line, Tumor
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry*
-
Enzyme Inhibitors / pharmacology*
-
Enzyme Inhibitors / therapeutic use
-
Female
-
Humans
-
Mice
-
Mice, SCID
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / metabolism
-
Sterol Esterase / antagonists & inhibitors*
-
Sterol Esterase / metabolism
-
Structure-Activity Relationship
Substances
-
Carbamates
-
Enzyme Inhibitors
-
Carboxylic Ester Hydrolases
-
Nceh1 protein, mouse
-
NCEH1 protein, human
-
Sterol Esterase